University of Nebraska Medical Center
University of Nebraska Medical Center

Tommy Martin COBRE Abstract

Project Summary

Heart failure is the leading cause of morbidity and mortality in the United States, and the only definitive ‘cure’ is a heart transplant. Donor hearts are far too few; however, evidence from the past two decades indicates that a small subset of patients with heart failure experience significant recovery of cardiac function with current guideline-directed therapies.

 Nevertheless, the molecular mechanisms that contribute to this favorable outcome are unknown, making it impossible to develop therapies that directly target cardiac recovery for all patients. Studying samples from patients treated with left ventricular assist device (LVAD), the therapy most often linked to recovery, we found that phosphorylation of

Ca2+/calmodulin-dependent kinase IIδ (CaMKIIδ) at serine 332 (S332), immediately downstream of a nuclear localization sequence (NLS), reliably predicted outcomes. Our follow-up mechanistic studies showed that S332 phosphorylation prevented nuclear translocation of CaMKIIδ, leading to impaired cardiomyocyte contractility and unresponsiveness to cardiac stress in patients who did not recover function with LVAD.

 In contrast, dephosphorylation at S332 in LVAD responder patients enabled stress-dependent nuclear targeting that was associated with maintenance of contractility. In this

proposal, we will investigate the regulation and function of nuclear CaMKIIδ and explore CaMKIIδ subcellular localization as a therapeutic target for cardiac recovery. The regulation of CaMKIIδ subcellular localization and the nuclear vs. cytoplasmic substrates of this kinase are incompletely defined.

 In Aim 1, we will determine the nuclear importer, define the nuclear and cytoplasmic substrates, and identify the S332 regulatory kinase. We will use co-expression and co-immunoprecipitation studies to determine which importin-α isoform(s) bind the CaMKIIδ NLS; identify nuclear and cytoplasmic substrates using

TurboID proximity labeling proteomics; and use affinity purification mass spectrometry with a CaMKIIδ NLS decoy peptide to identify regulatory kinases.

 To test the hypothesis that cytoplasmic CaMKIIδ causes heart failure, in Aim 2, we will deliver cytoplasm-restricted or nuclear-targeted CaMKIIδ to the hearts of CAMK2D knockout mice using adeno-associated viruses (AAVs) and monitor in vivo cardiac function by echocardiography. Fibrosis, apoptosis, and gene expression will be measured post-mortem to assess induction of pathological remodeling. Finally, our data show that S332 phosphorylation status predicts potential for cardiac recovery with LVAD; however, cardiac tissue biomarkers are too invasive to be widely adopted clinically. Plasma represents a more accessible source of biological information and circulating CaMKIIδ is abundant.

 Therefore, in Aim 3, we will quantify pre-LVAD plasma p-S332 by ELISA and determine whether it predicts LV functional recovery, measured by absolute change in LV ejection fraction post-LVAD. Completion of these studies will determine whether targeting CaMKIIδ subcellular localization represents a novel therapeutic strategy for heart failure and may provide the first circulating biomarker to guide implanting LVADs as a bridge-to-recovery.